🇺🇸 LAMIVUDINE, NEVIRAPINE, AND STAVUDINE in United States

LAMIVUDINE, NEVIRAPINE, AND STAVUDINE (LAMIVUDINE, NEVIRAPINE, AND STAVUDINE) regulatory status in United States.

Marketing authorisations

FDA

  • Status: approved

FDA

  • Application: NDA022537
  • Marketing authorisation holder: MACLEODS PHARMA
  • Local brand name: LAMIVUDINE, NEVIRAPINE, AND STAVUDINE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

FDA

  • Application: NDA200244
  • Marketing authorisation holder: HETERO DRUGS LTD
  • Local brand name: LAMIVUDINE, NEVIRAPINE, AND STAVUDINE
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

LAMIVUDINE, NEVIRAPINE, AND STAVUDINE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is LAMIVUDINE, NEVIRAPINE, AND STAVUDINE approved in United States?

Yes. FDA has authorised it; FDA has authorised it; FDA has authorised it.

Who is the marketing authorisation holder for LAMIVUDINE, NEVIRAPINE, AND STAVUDINE in United States?

MACLEODS PHARMA is the originator. The local marketing authorisation holder may differ — check the official source linked above.